FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077647940> ?p ?o ?g. }

• W2077647940 endingPage "1269" @default.
• W2077647940 startingPage "1261" @default.
• W2077647940 abstract "Background & AimsThere are no prospective, multicenter, double-blind, placebo-controlled, randomized pharmacologic trials for the treatment of pain-predominant functional gastrointestinal disorders in children. The aim of this study was to evaluate the efficacy of amitriptyline in children with pain-predominant functional gastrointestinal disorders.MethodsIn this multicenter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or functional dyspepsia were randomized to 4 weeks of placebo or amitriptyline (10 mg/d, weight <35 kg; 20 mg/d, weight >35 kg). Assessment of gastrointestinal symptoms, psychological traits, and daily activities occurred before and after intervention. Pain was assessed daily with self-report diaries. The primary outcome was overall response to treatment (child's assessment of pain relief and sense of improvement). Secondary outcomes were effect on psychosocial traits and daily functioning.ResultsNinety children were enrolled, and 83 completed the study (placebo, 40 children [30 girls]; drug, 43 children [35 girls]). A total of 63% of patients reported feeling better and 5% feeling worse in the amitriptyline arm compared with 57.5% feeling better and 2.5% feeling worse in the placebo arm (P = .63). Pain relief was excellent in 7% and good in 38% of children receiving placebo compared with excellent in 15% and good in 35% of children treated with amitriptyline (P = .85). Logistic regression analysis of those reporting excellent or good response versus fair, poor, or failed response showed no difference between amitriptyline and placebo (P = .83). Children who had more severe pain at baseline in both groups (P = .0065) had worse outcome. Amitriptyline reduced anxiety scores (P < .0001).ConclusionsBoth amitriptyline and placebo were associated with excellent therapeutic response. There was no significant difference between amitriptyline and placebo after 4 weeks of treatment. Patients with mild to moderate intensity of pain responded better to treatment. There are no prospective, multicenter, double-blind, placebo-controlled, randomized pharmacologic trials for the treatment of pain-predominant functional gastrointestinal disorders in children. The aim of this study was to evaluate the efficacy of amitriptyline in children with pain-predominant functional gastrointestinal disorders. In this multicenter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or functional dyspepsia were randomized to 4 weeks of placebo or amitriptyline (10 mg/d, weight <35 kg; 20 mg/d, weight >35 kg). Assessment of gastrointestinal symptoms, psychological traits, and daily activities occurred before and after intervention. Pain was assessed daily with self-report diaries. The primary outcome was overall response to treatment (child's assessment of pain relief and sense of improvement). Secondary outcomes were effect on psychosocial traits and daily functioning. Ninety children were enrolled, and 83 completed the study (placebo, 40 children [30 girls]; drug, 43 children [35 girls]). A total of 63% of patients reported feeling better and 5% feeling worse in the amitriptyline arm compared with 57.5% feeling better and 2.5% feeling worse in the placebo arm (P = .63). Pain relief was excellent in 7% and good in 38% of children receiving placebo compared with excellent in 15% and good in 35% of children treated with amitriptyline (P = .85). Logistic regression analysis of those reporting excellent or good response versus fair, poor, or failed response showed no difference between amitriptyline and placebo (P = .83). Children who had more severe pain at baseline in both groups (P = .0065) had worse outcome. Amitriptyline reduced anxiety scores (P < .0001). Both amitriptyline and placebo were associated with excellent therapeutic response. There was no significant difference between amitriptyline and placebo after 4 weeks of treatment. Patients with mild to moderate intensity of pain responded better to treatment." @default.
• W2077647940 created "2016-06-24" @default.
• W2077647940 creator A5002956177 @default.
• W2077647940 creator A5007647088 @default.
• W2077647940 creator A5008886001 @default.
• W2077647940 creator A5012432554 @default.
• W2077647940 creator A5024629646 @default.
• W2077647940 creator A5043206314 @default.
• W2077647940 creator A5062274159 @default.
• W2077647940 date "2009-10-01" @default.
• W2077647940 modified "2023-10-01" @default.
• W2077647940 title "Multicenter, Randomized, Placebo-Controlled Trial of Amitriptyline in Children With Functional Gastrointestinal Disorders" @default.
• W2077647940 cites W1580080219 @default.
• W2077647940 cites W16656950 @default.
• W2077647940 cites W1979079351 @default.
• W2077647940 cites W1988590138 @default.
• W2077647940 cites W1991905967 @default.
• W2077647940 cites W1996294605 @default.
• W2077647940 cites W1998058162 @default.
• W2077647940 cites W2010971619 @default.
• W2077647940 cites W2013286604 @default.
• W2077647940 cites W2014524519 @default.
• W2077647940 cites W2015016837 @default.
• W2077647940 cites W2024414619 @default.
• W2077647940 cites W2035917123 @default.
• W2077647940 cites W2037989606 @default.
• W2077647940 cites W2057286828 @default.
• W2077647940 cites W2059804477 @default.
• W2077647940 cites W2086872452 @default.
• W2077647940 cites W2095024518 @default.
• W2077647940 cites W2136587464 @default.
• W2077647940 cites W2137044513 @default.
• W2077647940 cites W2145231561 @default.
• W2077647940 cites W2156532019 @default.
• W2077647940 cites W2161151481 @default.
• W2077647940 cites W2163886973 @default.
• W2077647940 cites W2166664772 @default.
• W2077647940 cites W2168058358 @default.
• W2077647940 cites W2320505360 @default.
• W2077647940 cites W34506782 @default.
• W2077647940 cites W4250654462 @default.
• W2077647940 doi "https://doi.org/10.1053/j.gastro.2009.06.060" @default.
• W2077647940 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2827243" @default.
• W2077647940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19596010" @default.
• W2077647940 hasPublicationYear "2009" @default.
• W2077647940 type Work @default.
• W2077647940 sameAs 2077647940 @default.
• W2077647940 citedByCount "208" @default.
• W2077647940 countsByYear W20776479402012 @default.
• W2077647940 countsByYear W20776479402013 @default.
• W2077647940 countsByYear W20776479402014 @default.
• W2077647940 countsByYear W20776479402015 @default.
• W2077647940 countsByYear W20776479402016 @default.
• W2077647940 countsByYear W20776479402017 @default.
• W2077647940 countsByYear W20776479402018 @default.
• W2077647940 countsByYear W20776479402019 @default.
• W2077647940 countsByYear W20776479402020 @default.
• W2077647940 countsByYear W20776479402021 @default.
• W2077647940 countsByYear W20776479402022 @default.
• W2077647940 countsByYear W20776479402023 @default.
• W2077647940 crossrefType "journal-article" @default.
• W2077647940 hasAuthorship W2077647940A5002956177 @default.
• W2077647940 hasAuthorship W2077647940A5007647088 @default.
• W2077647940 hasAuthorship W2077647940A5008886001 @default.
• W2077647940 hasAuthorship W2077647940A5012432554 @default.
• W2077647940 hasAuthorship W2077647940A5024629646 @default.
• W2077647940 hasAuthorship W2077647940A5043206314 @default.
• W2077647940 hasAuthorship W2077647940A5062274159 @default.
• W2077647940 hasBestOaLocation W20776479401 @default.
• W2077647940 hasConcept C126322002 @default.
• W2077647940 hasConcept C142724271 @default.
• W2077647940 hasConcept C168563851 @default.
• W2077647940 hasConcept C1862650 @default.
• W2077647940 hasConcept C204787440 @default.
• W2077647940 hasConcept C27081682 @default.
• W2077647940 hasConcept C2775965419 @default.
• W2077647940 hasConcept C2778271842 @default.
• W2077647940 hasConcept C2780216858 @default.
• W2077647940 hasConcept C2780820201 @default.
• W2077647940 hasConcept C2780955771 @default.
• W2077647940 hasConcept C2992435398 @default.
• W2077647940 hasConcept C42219234 @default.
• W2077647940 hasConcept C71924100 @default.
• W2077647940 hasConceptScore W2077647940C126322002 @default.
• W2077647940 hasConceptScore W2077647940C142724271 @default.
• W2077647940 hasConceptScore W2077647940C168563851 @default.
• W2077647940 hasConceptScore W2077647940C1862650 @default.
• W2077647940 hasConceptScore W2077647940C204787440 @default.
• W2077647940 hasConceptScore W2077647940C27081682 @default.
• W2077647940 hasConceptScore W2077647940C2775965419 @default.
• W2077647940 hasConceptScore W2077647940C2778271842 @default.
• W2077647940 hasConceptScore W2077647940C2780216858 @default.
• W2077647940 hasConceptScore W2077647940C2780820201 @default.
• W2077647940 hasConceptScore W2077647940C2780955771 @default.
• W2077647940 hasConceptScore W2077647940C2992435398 @default.
• W2077647940 hasConceptScore W2077647940C42219234 @default.
• W2077647940 hasConceptScore W2077647940C71924100 @default.
• W2077647940 hasIssue "4" @default.

• next